Přihlásit se Zaregistrujte se zdarma

Vydané akcie společnosti Cue Biopharma Inc

Jaká je hodnota metriky Vydané akcie společnosti Cue Biopharma Inc?

Hodnota metriky Vydané akcie společnosti Cue Biopharma Inc je 48.643M

Jaká je definice metriky Vydané akcie?



Vydané akcie (Shares outstanding) je počet všech akcií společnosti nebo finančních aktiv, které byly autorizované, vydané a koupené investory a jsou jimi vlastněné.

Shares outstanding includes all stock held by investors including both common shares held by the public and restricted shares owned by the company's internal managements. Shares outstanding have rights and represent an ownership in the corporation by the person who holds the shares. They are distinguished from treasury shares, which are shares held by the corporation itself and have no exercisable rights. Shares outstanding plus treasury shares together amount to the number of issued shares.

Shares outstanding can be calculated as either basic or fully diluted. The basic count is the current number of shares. Dividend distributions and voting in the general meeting of shareholders are calculated according to this number. The fully diluted shares outstanding count, on the other hand, includes diluting securities, such as warrants, capital notes or convertibles. If the company has any diluting securities, this indicates the potential future increased number of shares outstanding. A company's market capitalization is calculated by multiplying the price of one of its shares by the total number outstanding shares a company has issued.

Vydané akcie společností v sektoru Health Care sektor na NASDAQ ve srovnání se společností Cue Biopharma Inc

Čemu se věnuje společnost Cue Biopharma Inc?

cue biopharma is an innovative immunotherapy company developing a novel, proprietary class of biologics engineered to selectively modulate the human immune system to treat a broad range of cancers and autoimmune disorders. we design biologics to engage and modulate the activity of disease-associated t cells in the patient’s body, offering significant therapeutic advantages while potentially minimizing or eliminating unwanted side effects. we believe our biologics allow us to target antigen-specific t cell populations in a variety of indications using a simple peptide exchange within previously-validated drug frameworks developed from the cue biologics platform. this flexibility could truncate the drug selection and development process, moving effective therapeutics from discovery to clinical validation more rapidly and cost efficiently than current industry standard timelines and costs. headquartered in kendall square, cambridge, ma, we are led by an experienced management team and sci

Firmy s metrikou vydané akcie podobnou společnosti Cue Biopharma Inc